探索大脑粉样血管病变:洞察病变发生,诊断和治疗的方法
Mariagiovanna Cozza1, Lucia Amadori1, Virginia Boccardi2
1Department of Integration, Intermediate Care Programme, AUSL Bologna, Italy.
Journal of the neurological sciences
|November 6, 2023
概括
大脑粉样蛋白血管病变 (CAA) 涉及大脑血管中的粉样蛋白β沉积,导致损伤和认知能力下降. 目前的治疗方法可以控制症状,而针对粉样蛋白清除的新疗法正在开发中.
科学领域:
- 神经学 神经学
- 血管生物学 血管生物学
- 神经退行性疾病 神经退行性疾病
背景情况:
- 大脑粉状血管病 (CAA) 是一种神经疾病,其标志是大脑血管中粉状斑块的积累.
- 在了解其机制,诊断和治疗方面,CAA带来了重大挑战.
- 在血管中 Amyloid beta (Aβ) 的积累会导致损伤,血流受损和认知能力下降.
研究的目的:
- 为了阐明脑粉样血管病变的发病,诊断和治疗.
- 突出基因和环境因素在CAA发展中的作用.
- 审查当前的诊断成像技术和治疗策略.
主要方法:
- 涉及粉样β (Aβ) 沉积的病变发生的审查.
- 讨论诊断工具,包括MRI和PET扫描用于粉样蛋白检测.
- 对CAA目前和实验性治疗方法的分析.
主要成果:
- CAA的发病包括Aβ沉积,导致血管损伤和认知障碍.
- 像MRI和PET这样的高级成像对于准确的CAA诊断至关重要.
- 没有特定的疾病修饰疗法存在,但实验性治疗方法显示出希望.
结论:
- 了解CAA的病原体是针对性干预的关键.
- 通过先进成像技术的早期诊断有助于管理并减少并发症风险.
- 目前正在进行的Aβ清除和抗炎疗法的临床试验为未来的治疗提供了希望.
相关概念视频
Alzheimer's Disease: Overview
498
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
498
Alzheimer's Disease: Treatment
197
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
197
Amyloid Fibrils
5.3K
5.3K


